Integrated systems toxicology identifies TCDD-responsive targets linked to immune dysregulation and treatment response in psoriasis

• by Xuan Zhang, Yankun Zhang, Yanling He

• May 29, 2026

Understanding the Perspectives and Experiences of Canadian Psoriasis Patients with Diverse Skin Tones

• by H. Chih-ho Hong, Tessa Carr, Frankie Tai, Saad Mirza, Omair Lakhani, Laura Park-Wyllie, Marissa Joseph

• April 9, 2026

Mandatory Training Modules Deserve a Harder Look

A JAMA Viewpoint argues that 4 million physician-hours spent on compliance modules each year warrants institutional reassessment.

• by Kerri Miller

• April 16, 2026

• 3 min

FDA Clears Golimumab Biosimilars

New biosimilars enter the market with pharmacy-level substitution eligibility for rheumatology and gastroenterology indications.

• by Kathryn Wighton

• May 18, 2026

• 2 min